ARTICANZ - Beta (ver 0.91)
Annotated Registry of Trials in Cancer, Australia and New Zealand Ed.
- Results - location/QLD/4032-Chermside-Icon-Cancer-Care-Chermside
Home
By cancer type
By drug class
By site
Data
FAQ
About
⚠
ARTICANZ provides informational content about cancer drug trials in Australia/NZ that is updated weekly but may not be completely accurate, and should not replace medical advice from qualified healthcare professionals. The platform is intended to be useful, providing information "as is" without warranties. Non-medical users must always consult healthcare providers for all clinical decisions.
Search results
6
trial(s) found.
NCT07028853
Advanced
Phase 3
Recruiting
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Mevrometostat (PF-06821497) With Enzalutamide in Metastatic Castration-Sensitive Prostate Cancer (MEVPRO-3) (
C2321008
)
EZH2 inhibitor
antiandrogen,nonsteroidal,second generation
placebo
Castrate-sensitive prostate cancer
Prostate cancer
NSW
2076 - Wahroonga - Sydney Adventist Hospital
2800 - Orange - Orange Hospital-Cancer Centre Clinical Trials Unit
QLD
4032 - Chermside - Icon Cancer Care Chermside
4101 - South Brisbane - Mater Hospital Brisbane / ICON Cancer Centre
SA
5037 - Kurralta Park - Icon Cancer Centre Adelaide
WA
6009 - Nedlands - Sir Charles Gairdner Hospital - WA Cancer Centre
NZ
NZ.3112 - Tauranga - Tauranga Hospital, Bay of Plenty Clinical Trials Unit
NZ.3210 - Hamilton - Waikato Hospital
NZ.4442 - Roslyn - Palmerston North Hospital Cancer Centre - Palmerston North Hospital
NCT06697301
Advanced
Phase 2 / Phase 3
Recruiting
A Multicenter, Randomized, Double-Blind, Active Comparator-Controlled, Adaptive Phase 2/3 Study to Evaluate the Safety and Efficacy of EIK1001 and Pembrolizumab Versus Placebo and Pembrolizumab as First-Line Therapy in Participants With Advanced Melanoma (TeLuRide-006) (
EIK1001-006
)
TLR7/TLR8 agonist
anti-PD-1 monoclonal antibody
placebo
Melanoma
NSW
2500 - Wollongong - Cancer Care Wollongong
VIC
3128 - Box Hill - Box Hill Hospital - Eastern Health
QLD
4032 - Chermside - Icon Cancer Care Chermside
SA
5042 - Bedford Park - Flinders Medical Centre
NZ
NZ.1023 - Grafton - Auckland City Hospital - Cancer & Blood Research
NZ.8011 - Christchurch - Canterbury District Health Board - Christchurch Hospital Cancer Centre
NCT06594926
Curative
Phase 2
Recruiting
Evaluating the Efficacy of Bipolar Androgen Therapy in Extending Metastasis-free Survival in Patients With M0 Castrate-resistant Prostate Cancer With PSA Progression But Not Radiological or Clinical Progression on Darolutamide (
WOMBAT
)
antiandrogen,nonsteroidal,second generation
Prostate cancer
NSW
2010 - Darlinghurst - St Vincent's Hospital Sydney - The Kinghorn Cancer Centre
2065 - St Leonards - GenesisCare North Shore Private Hospital
2076 - Wahroonga - Sydney Adventist Hospital
2640 - Albury - Border Medical Oncology Research Unit
ACT
2605 - Garran - The Canberra Hospital
VIC
3128 - Box Hill - Box Hill Hospital - Eastern Health
3144 - Malvern - Cabrini Health, Cabrini Cancer Care Centre
3350 - Ballarat - Grampians Health Service's Ballarat Base Hospital
3677 - Wangaratta - Northeast Health Wangaratta
QLD
4032 - Chermside - Icon Cancer Care Chermside
4101 - South Brisbane - Mater Hospital Brisbane / ICON Cancer Centre
SA
5000 - Adelaide - Royal Adelaide Hospital - Adelaide Cancer Centre
NCT06172478
Advanced
Phase 2
Recruiting
HERTHENA-PanTumor01 (
U31402-277
): A Phase 2, Multicenter, Multicohort, Open-Label, Proof of Concept Study of Patritumab Deruxtecan (HER3-DXd; U3-1402) in Subjects With Locally Advanced or Metastatic Solid Tumors
anti-ERBB3 antibody-drug conjugate
Bladder cancer
Cervical cancer
Endometrial cancer
Gastric cancer
Gastroesophageal cancer
Head and neck squamous cell carcinoma
High-grade serous ovarian cancer
Melanoma
Oesophageal cancer
Pancreatic adenocarcinoma
Prostate adenocarcinoma
NSW
2050 - Camperdown - Chris O'Brien Lifehouse
VIC
3168 - Clayton - Monash Medical Centre
QLD
4032 - Chermside - Icon Cancer Care Chermside
4812 - Hyde Park - Icon Cancer Centre Townsville
TAS
7000 - Hobart - ICON Cancer Care Hobart
NCT05128825
Advanced
Phase 2
Recruiting
A Phase 2 Open-Label, Multicenter Study To Evaluate Efficacy And Safety Of ZN-c3 In Subjects With High-Grade Serous Ovarian, Fallopian Tube, Or Primary Peritoneal Cancer (
DENALI
/ ZN-c3-005 / GOG-3066)
WEE1 inhibitor
High-grade serous ovarian cancer
Ovarian cancer
Primary fallopian tube serous carcinoma
Primary peritoneal serous carcinoma
VIC
3002 - East Melbourne - Epworth Freemasons
QLD
4032 - Chermside - Icon Cancer Care Chermside
4101 - South Brisbane - Mater Hospital Brisbane / ICON Cancer Centre
SA
5037 - Kurralta Park - Icon Cancer Centre Adelaide
5065 - Toorak Gardens - Burnside War Memorial Hospital
WA
6008 - Subiaco - Bendat Family Comprehensive Cancer Centre - St John of God Subiaco Hospital
6009 - Nedlands - Sir Charles Gairdner Hospital - WA Cancer Centre
NCT07000149
Advanced
Phase 3
Active not recruiting
A Phase Ib/III Randomized, Multicenter, Global Study of Volrustomig Plus Casdatifan or Volrustomig Monotherapy Versus Nivolumab Plus Ipilimumab as First-line Treatment for Participants With Advanced Clear Cell Renal Cell Carcinoma (ccRCC) (
eVOLVE-RCC02
)
HIF2a inhibitor
anti-CTLA4 monoclonal antibody
anti-PD-1 monoclonal antibody
bispecific PD-L1/CTLA4 antibody
Clear cell renal cell carcinoma
VIC
3002 - East Melbourne - Epworth Freemasons
QLD
4032 - Chermside - Icon Cancer Care Chermside
SA
5000 - Adelaide - Royal Adelaide Hospital - Adelaide Cancer Centre
5112 - Elizabeth Vale - Lyell McEwin Hospital
Additional search terms:
API and Webpage URLs:
Copy /Bookmark
Filters
Recruitment Status
Recruiting (5)
Active not recruiting (1)
Recruitment Country and State
QLD (6)
SA (5)
VIC (5)
NSW (4)
NZ (2)
WA (2)
ACT (1)
TAS (1)
Phase
Phase 2 (3)
Phase 2 / Phase 3 (1)
Phase 3 (2)
Trial Type
Advanced (5)
Curative (1)
Cancer Therapy Class
AR
33%
androgen axis
33%
PD-1
33%
PD-1/PD-L1
33%
EZH2
17%
TLR7/TLR8
17%
LHRH
17%
oestrogen axis
17%
ERBB3
17%
WEE1
17%
CTLA4
17%
HIF2a
17%
PD-L1
17%
Facility
4032 - Chermside - Icon Cancer Care Chermside (6)
4101 - South Brisbane - Mater Hospital Brisbane / ICON Cancer Centre (3)
2076 - Wahroonga - Sydney Adventist Hospital (2)
5037 - Kurralta Park - Icon Cancer Centre Adelaide (2)
6009 - Nedlands - Sir Charles Gairdner Hospital - WA Cancer Centre (2)
3128 - Box Hill - Box Hill Hospital - Eastern Health (2)
5000 - Adelaide - Royal Adelaide Hospital - Adelaide Cancer Centre (2)
3002 - East Melbourne - Epworth Freemasons (2)
2800 - Orange - Orange Hospital-Cancer Centre Clinical Trials Unit (1)
NZ.3112 - Tauranga - Tauranga Hospital, Bay of Plenty Clinical Trials Unit (1)
NZ.3210 - Hamilton - Waikato Hospital (1)
NZ.4442 - Roslyn - Palmerston North Hospital Cancer Centre - Palmerston North Hospital (1)
2500 - Wollongong - Cancer Care Wollongong (1)
5042 - Bedford Park - Flinders Medical Centre (1)
NZ.1023 - Grafton - Auckland City Hospital - Cancer & Blood Research (1)
NZ.8011 - Christchurch - Canterbury District Health Board - Christchurch Hospital Cancer Centre (1)
2010 - Darlinghurst - St Vincent's Hospital Sydney - The Kinghorn Cancer Centre (1)
2065 - St Leonards - GenesisCare North Shore Private Hospital (1)
2605 - Garran - The Canberra Hospital (1)
2640 - Albury - Border Medical Oncology Research Unit (1)
3144 - Malvern - Cabrini Health, Cabrini Cancer Care Centre (1)
3350 - Ballarat - Grampians Health Service's Ballarat Base Hospital (1)
3677 - Wangaratta - Northeast Health Wangaratta (1)
2050 - Camperdown - Chris O'Brien Lifehouse (1)
3168 - Clayton - Monash Medical Centre (1)
4812 - Hyde Park - Icon Cancer Centre Townsville (1)
7000 - Hobart - ICON Cancer Care Hobart (1)
5065 - Toorak Gardens - Burnside War Memorial Hospital (1)
6008 - Subiaco - Bendat Family Comprehensive Cancer Centre - St John of God Subiaco Hospital (1)
5112 - Elizabeth Vale - Lyell McEwin Hospital (1)
Cancer Type
Cancer
Solid tumour
Urogenital cancer
Male genital cancers
Prostate cancer
Prostate adenocarcinoma
Melanoma
Epithelial Ovarian Cancer
Gynaecological cancer
High-grade serous carcinoma of the ovary, fallopian tube, and peritoneum
High-grade serous ovarian cancer
Ovarian adenocarcinoma
Ovarian cancer
Ovarian serous carcinoma
Castrate-sensitive prostate cancer
Bladder cancer
Cervical cancer
Endometrial cancer
Exocrine pancreatic cancer
Gastric cancer
Gastroesophageal cancer
Gastrointestinal cancer
HPV-related cancer
HPV16-positive cancer
Head and neck cancer
Head and neck squamous cell carcinoma
Oesophageal cancer
Pancreatic adenocarcinoma
Pancreatic cancer
Pancreatobiliary cancer
Thoracic cancer
Upper gastrointestinal cancer
Viral-related cancer
Fallopian tube cancer
Peritoneal cancer
Primary fallopian tube serous carcinoma
Primary peritoneal serous carcinoma
Clear cell renal cell carcinoma
Kidney cancer
URLs for this search
API URL:
Copy
Bookmarkable URL:
Copy